Venture
Rivus Pharmaceuticals, Inc.
Latest Form D 2025-01-16- CIK 1773293
- State VA
- Pharmaceuticals
- 4 Form D offerings since 2021-10-04
- Total sold
- $223M
- across 4 offerings
- Rounds
- 4
- Form D offerings since 2021-10-04
- Latest round
- $57M
- 2025-01-16 · 021-535494
- Investors
- 7
- on the latest round
Connected
named in its Form D filingsOfferings · since 2021-10-044 Form D offeringsExemptions506(b)People · Item 3Allen Cunningham + 9 moreInvestors · dashboard1 inferred investor
Rivus Pharmaceuticals, Inc.CIK 1773293
Round timeline
amount sold · by first filed2025-01-16 · $57M
- 2021-10-04$34.5M021-415561
- 2024-09-17$66M021-524175
- 2024-09-17$66M021-524179
- 2025-01-16$57M021-535494
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($66M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-535494 | First filed2025-01-16 | Latest2025-01-16 | Sought$57M | Sold$57M | Investors7 | Exemptions506(b) |
| 021-524179 | First filed2024-09-17 | Latest2024-09-17 | Sought$66M | Sold$66M | Investors7 | Exemptions506(b) |
| 021-524175 | First filed2024-09-17 | Latest2024-09-17 | Sought$66M | Sold$66M | Investors7 | Exemptions506(b) |
| 021-415561 | First filed2021-10-04 | Latest2021-10-04 | Sought$35M | Sold$34.5M | Investors4 | Exemptions506(b) |
Who backs Rivus Pharmaceuticals, Inc. — 1 inferred investor — and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2025-01-16
| Name | Relationship |
|---|---|
| Allen Cunningham | RelationshipExecutive Officer, Director |
| Jayson Dallas | RelationshipExecutive Officer, Director |
| Shaharyar Khan | RelationshipExecutive Officer, Director |
| Tom O'Neil | RelationshipExecutive Officer |
| Rick Winningham | RelationshipDirector |
| Francesco De Rubertis | RelationshipDirector |
| Ian Smith | RelationshipDirector |
| Erin Lavelle | RelationshipDirector |
| Robert Schott | RelationshipExecutive Officer |
| Derek DiRocco | RelationshipDirector |
Facts
As its latest Form D states them
- Industry
- Pharmaceuticals
- State
- Virginia (VA)
- Exemptions
- Rule 506(b)
- First filed
- 2021-10-04
- Latest filing
- 2025-01-16
Who backs Rivus Pharmaceuticals, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗